UY26041A1 - BICYCLE HETERO CYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION - Google Patents

BICYCLE HETERO CYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION

Info

Publication number
UY26041A1
UY26041A1 UY26041A UY26041A UY26041A1 UY 26041 A1 UY26041 A1 UY 26041A1 UY 26041 A UY26041 A UY 26041A UY 26041 A UY26041 A UY 26041A UY 26041 A1 UY26041 A1 UY 26041A1
Authority
UY
Uruguay
Prior art keywords
group
alkylene
substituted
atom
optionally substituted
Prior art date
Application number
UY26041A
Other languages
Spanish (es)
Inventor
Dr Frank Himmelsbach
Dr Elke Langkopf
Dr Birgit Jung
Dr Thomas Metz
Dr Flavio Solca
Dr Stefan Blech
Original Assignee
Boehringer Ingelheim Pharma
Amp
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999108567 external-priority patent/DE19908567A1/en
Priority claimed from DE1999111366 external-priority patent/DE19911366A1/en
Priority claimed from DE1999128306 external-priority patent/DE19928306A1/en
Priority claimed from DE19954816A external-priority patent/DE19954816A1/en
Application filed by Boehringer Ingelheim Pharma, Amp, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY26041A1 publication Critical patent/UY26041A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Heterociclos bicíclicos de la fórmula general (I), en donde: Ra contiene un átomo de hidrógeno o un grupo alquilo; Rb contiene un grupo fenilo, bencilo ó 1-feniletilo, en los que el núcleo de fenilo está sustituido; Rc y Rd, que pueden ser iguales o diferentes, contienen en cada caso un átomo de hidrógeno, flúor o cloro, un grupo metoxi o metilo eventualmente sustituido; X contiene un grupo metino sustituido con un grupo ciano, o un átomo de nitrógeno; A contiene un átomo de oxígeno o un grupo imino eventualmente sustituido con un grupo alquilo; B contiene un grupo carbonilo o sulfonilo; C contiene un grupo 1,3-alenileno, 1,1- ó 1,2-vinileno, que en cada caso pueden estar sustituidos, un grupo etinileno o un grupo 1,3-butadien-1,4-ileno eventualmente sustituido; D contiene grupo alquileno, CO-alquileno o SO2-alquileno, o en el caso de que D esté unido a un átomo de carbono del radical E, contiene también un enlace o, en el caso de que D esté unido a un átomo de nitrógeno del radical E, contiene también un grupo carbonilo o sulfonilo; E contiene un grupo R6O-CO-alquilen-NR5, (R7O-PO-OR8)-alquilen-NR5 ó (R7O-PO-R9)-alquilen-NR5. Por ejemplo: 4-((3-bromofenil)amino)-7-(3-(4-((etoxicarbonil)metil)-piperazin-1-il)propiloxi)-6-((vinilcarbonil)amino)-quinazolina. La invención presenta también sus tautómeros, sus esteroisómeros y sus sales, en particular sus sales fisiologicamente compatibles con ácidos o bases inorgánicas u rogánicas, que presentan valiosas propiedades farmacológicas, en particular un efecto inhibidor sobre las transducción de senales inducidas por tirosina-quinasas, a su empleo para el tratamiento de enfermedades, en particular tumorales. pulmonares y de las vías respiratorias, y a su preparación.Bicyclic heterocycles of the general formula (I), wherein: Ra contains a hydrogen atom or an alkyl group; Rb contains a phenyl, benzyl or 1-phenylethyl group, in which the phenyl nucleus is substituted; Rc and Rd, which may be the same or different, each contain a hydrogen, fluorine or chlorine atom, an optionally substituted methoxy or methyl group; X contains a methine group substituted with a cyano group, or a nitrogen atom; A contains an oxygen atom or an imino group optionally substituted with an alkyl group; B contains a carbonyl or sulfonyl group; C contains a 1,3-alelenylene, 1,1- or 1,2-vinylene group, which in each case can be substituted, an ethynylene group or an optionally substituted 1,3-butadien-1,4-ylene group; D contains alkylene, CO-alkylene or SO2-alkylene group, or in the case that D is attached to a carbon atom of radical E, it also contains a bond or, in the case that D is attached to a nitrogen atom of radical E, it also contains a carbonyl or sulfonyl group; E contains a group R6O-CO-alkylene-NR5, (R7O-PO-OR8) -alkylene-NR5 or (R7O-PO-R9) -alkylene-NR5. For example: 4 - ((3-bromophenyl) amino) -7- (3- (4 - ((ethoxycarbonyl) methyl) -piperazin-1-yl) propyloxy) -6 - ((vinylcarbonyl) amino) -quinazoline. The invention also presents its tautomers, its stereoisomers and its salts, in particular its physiologically compatible salts with inorganic or roganic acids or bases, which have valuable pharmacological properties, in particular an inhibitory effect on the transduction of signals induced by tyrosine kinases, to its use for the treatment of diseases, particularly tumors. lung and airways, and their preparation.

UY26041A 1999-02-27 2000-02-28 BICYCLE HETERO CYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION UY26041A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE1999108567 DE19908567A1 (en) 1999-02-27 1999-02-27 New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
DE1999111366 DE19911366A1 (en) 1999-03-15 1999-03-15 New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
DE1999128306 DE19928306A1 (en) 1999-06-21 1999-06-21 New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
DE19954816A DE19954816A1 (en) 1999-11-13 1999-11-13 New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases

Publications (1)

Publication Number Publication Date
UY26041A1 true UY26041A1 (en) 2000-09-29

Family

ID=37516076

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26041A UY26041A1 (en) 1999-02-27 2000-02-28 BICYCLE HETERO CYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION

Country Status (5)

Country Link
AR (1) AR031668A1 (en)
CO (1) CO5251386A1 (en)
EA (1) EA200100830A1 (en)
UY (1) UY26041A1 (en)
YU (1) YU60501A (en)

Also Published As

Publication number Publication date
CO5251386A1 (en) 2003-02-28
YU60501A (en) 2004-07-15
EA200100830A1 (en) 2002-04-25
AR031668A1 (en) 2003-10-01

Similar Documents

Publication Publication Date Title
ECSP034464A (en) BICYCLIC HETEROCICLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION
UY27078A1 (en) DERIVATIVES OF QUINAZOLINE, DRUGS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION
EA200701302A1 (en) 4- (N-PHYLENAMINO) QUINAZOLIN / -CHINOLINE AS THYROSINKINASE INHIBITORS
ECSP034646A (en) DERIVATIVES OF QUINAZOLINE, DRUGS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION
UY26659A1 (en) BICYCLIC HETERO CYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION
UY26899A1 (en) FUSIONATED PIRAZOL DERIVATIVES
CN101098873A (en) 1,4 substituted pyrazolopyrimidines as kinase inhibitors
UY24474A1 (en) PYRIMID (5,4-D) PYRIMIDINES, ANTITUMORAL MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION
EE9700211A (en) Pyrimido [5,4-d] pyrimidines, drugs containing these compounds, their use and method for their preparation
NO2015020I1 (en) Ceritinib, 5-chloro-N-5-methyl-4- (piperidin-4-yl) -2 - [(propan-2-yl) oxy] phenyl-N- [2- (propan-2-sulfonyl) phenyl] pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof
HUP9901820A2 (en) 4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their production
ATE348817T1 (en) 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES
YU90901A (en) Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
ATE380818T1 (en) PIPERAZINE-SUBSTITUTED ARYL-BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOSIS
UY26513A1 (en) NEW REPLACED PIPERIDINES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION.
AR060811A1 (en) MGLUR5 V MODULATORS
UY26902A1 (en) BICYCLIC HETEROCYCLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION
UY27767A1 (en) BICYCLIC HETEROCICLES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT, AND PROCEDURES FOR THEIR PREPARATION.
UY28191A1 (en) BICYCLIC HETEROCICLES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION.
CO5580825A2 (en) HEREROCICLIC DERIVATIVES OF GLICINAMIDE AND ITS MEDICAL USE
UY26067A1 (en) BICYCLE HETERO CYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURE
ECSP045330A (en) BICYCLIC HETEROCICLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURE FOR THEIR PREPARATION
ES2354039T3 (en) DERIVATIVES OF N-ARIL- {4- [7- (ALCOXI) QUINAZOLIN-4-IL] PIPERAZINIL} CARBOXAMIDE AS PDGFR INHIBITORS.
DE68909855D1 (en) 2 - [(4-Piperidinyl) methyl] -1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their therapeutic use.
UY26041A1 (en) BICYCLE HETERO CYCLES, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20100111